PATENT CLAIM ANALYSIS

Application Number: 16042475
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "464000"]

Abstract:
The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of autism spectrum disorders (ASD).

Claim (Index 15):
The pharmaceutical composition according to any of  claims 12  to  14 , wherein the wherein the at least one additional compound intended for preventing or treating ASD is selected from the group constituted of serotonine, buspirone, clomipramine, fenfluramine, fluoxetine, fluvoxamine, sertraline, dopamine, haloperidol, L-dopa, pimozide, epinephrine, norepinephrine, beta-blockers, clonidine, desipramine, opiate antagonists, ACTH, clozapine, risperidone, vitamins B6 and B12 and melatonin.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 95.0
- Lexical Diversity: 1.19355
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15004218', '15869672', '15038011', '13699087', '15687111']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7343626284500349
- 35 USC 102 Novelty (BERT): 0.5085874632390212
- Combined Prediction Score: 0.7117851119289335
- Mean Citation Score: 212.190992
- Max Citation Score: 225.72235
- Similarity Product: 151.19923977968398

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test